Revefenacin - Latest Advances

Stepwise Management of Status Asthmaticus Refractory to Initial Therapy: A Case Report.

Journal: Cureus

Published: May 02, 2025

Nebulized Long-Acting Bronchodilators to Treat Acute Respiratory Failure in an Older Adult: A Case Report.

Journal: Cureus

Published: March 07, 2025

Quantification and Aerodynamic Particle Size Distribution of Revefenacin Aerosol With UHPLC-MS/MS.

Journal: Journal of separation science

Published: February 05, 2025

Development of a novel stability-indicating UHPLC method for revefenacin quality control and impurity identification using 2D-LC-HRMS.

Journal: Journal of pharmaceutical and biomedical analysis

Published: January 10, 2025

Comparison table: Inhaled drugs for treatment of COPD.

Journal: The Medical letter on drugs and therapeutics

Published: August 26, 2024

Drugs for COPD.

Journal: The Medical letter on drugs and therapeutics

Published: August 26, 2024

Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD.

Journal: International journal of chronic obstructive pulmonary disease

Published: June 21, 2024

Estimating Tiotropium Wasted Doses After Adding Revefenacin to an Inpatient Formulary: A Single-Center Cross-Sectional Study.

Journal: Hospital pharmacy

Published: May 20, 2024

Molecular docking aided machine learning for the identification of potential VEGFR inhibitors against renal cell carcinoma.

Journal: Medical oncology (Northwood, London, England)

Published: March 27, 2024

Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression.

Journal: Chronic obstructive pulmonary diseases (Miami, Fla.)

Published: January 19, 2024

Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.

Journal: Respiratory medicine

Published: November 02, 2022

Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease.

Journal: Therapeutic advances in respiratory disease

Published: March 02, 2022

Filters

Stepwise Management of Status Asthmaticus Refractory to Initial Therapy: A Case Report.

Stepwise Management of Status Asthmaticus Refractory to Initial Therapy: A Case Report.

Nebulized Long-Acting Bronchodilators to Treat Acute Respiratory Failure in an Older Adult: A Case Report.

Nebulized Long-Acting Bronchodilators to Treat Acute Respiratory Failure in an Older Adult: A Case Report.

Quantification and Aerodynamic Particle Size Distribution of Revefenacin Aerosol With UHPLC-MS/MS.

Quantification and Aerodynamic Particle Size Distribution of Revefenacin Aerosol With UHPLC-MS/MS.

Development of a novel stability-indicating UHPLC method for revefenacin quality control and impurity identification using 2D-LC-HRMS.

Development of a novel stability-indicating UHPLC method for revefenacin quality control and impurity identification using 2D-LC-HRMS.

Comparison table: Inhaled drugs for treatment of COPD.

Comparison table: Inhaled drugs for treatment of COPD.

Drugs for COPD.

Drugs for COPD.

Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD.

Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD.

Estimating Tiotropium Wasted Doses After Adding Revefenacin to an Inpatient Formulary: A Single-Center Cross-Sectional Study.

Estimating Tiotropium Wasted Doses After Adding Revefenacin to an Inpatient Formulary: A Single-Center Cross-Sectional Study.

Molecular docking aided machine learning for the identification of potential VEGFR inhibitors against renal cell carcinoma.

Molecular docking aided machine learning for the identification of potential VEGFR inhibitors against renal cell carcinoma.

Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression.

Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression.

Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.

Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.

Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease.

Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease.